Nicola Greenlaw

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Paul R. Kalra, John G.F. Cleland, Mark C. Petrie et al. · The Lancet · 2022 · 372 citations · Full text

Medicine, Cardiology, Internal Medicine +11

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

John R. Petrie, Nish Chaturvedi, Ian Ford et al. · The Lancet Diabetes & Endocrinology · 2017 · 347 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +14

Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial

Anthony D. Ormerod, Kim S Thomas, Fiona E. Craig et al. · BMJ · 2015 · 261 citations · Full text

Medicine, Dermatology, Pharmacotherapy +9

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial

Isla S. Mackenzie, Christopher J. Hawkey, Ian Ford et al. · The Lancet · 2022 · 157 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +16

Intravenous Ferric Carboxymaltose in Iron-Deficient Chronic Heart Failure Patients with and Without Anaemia: a Subanalysis of the FAIR-HF Trial

Gerasimos Filippatos, Dimitrios Farmakis, Josep Comín Colet et al. · European Journal of Heart Failure · 2013 · 156 citations · Full text

Medicine, Cardiology, Internal Medicine +14